B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $29-Report Released on 2 February 2024
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on TG Therapeutics (NASDAQ:TGTX) and raises the price target from $24 to $29 as of 2 February 2024.
February 05, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities maintains a Buy rating on TG Therapeutics and increases the price target from $24 to $29.
The increase in price target by a reputable analyst firm like B. Riley Securities typically signals a strong bullish outlook on the stock, suggesting potential upside. This could lead to increased investor confidence and a short-term rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100